Lan Deng

机构：Tianjin Agricultural University, Shanghai Jiao Tong University, Foshan Maternity and Child Health Care Hospital, Beijing Academy of Agricultural and Forestry Sciences, Hubei Engineering University, Shanghai Ocean University · ORCID：0000-0003-0643-7652

发表论文 88 篇 · 总被引 1465 次 · h-index 20

代表论文

Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial (2023 · The Lancet Haematology · 被引 72)
Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial (2023 · Journal of Hematology & Oncology · 被引 72)
Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III Trial (2022 · Journal of Clinical Oncology · 被引 53)
Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia (2022 · Journal of Internal Medicine · 被引 44)
Systemic investigation of inetetamab in combination with small molecules to treat HER2-overexpressing breast and gastric cancers (2023 · Open Life Sciences · 被引 25)
Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory/relapsed acute myeloid leukemia with FLT3‐ITD : A multicenter phase 2 study (2023 · Journal of Internal Medicine · 被引 22)